Drug Approval | May 26, 2022
Zydus Lifesciences receives final approval from USFDA for Pemetrexed for Injection
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March’22)
According to GlobalData’s ‘Pharmaceutical Intelligence Center’, the number of diagnosed prevalent cases of ALK-mutant NSCLC in China is estimated to grow at a CAGR of 5.3% from 22,725 in 2021 to 31,902 in 2029
The tablets have an estimated market size of US $ 548 million for twelve months ending December 2021 according to IQVIA
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
According to IQVIA sales data for the 12-month period ending March 2022, the Zytiga tablets, 500 mg market achieved annual sales of approximately US $ 260.2 million
A post approval change order is often necessary, but innovators should plan and prepare for this pre-approval. Planning alongside outsourcing partners will help ensure that only a small-scale study is needed—not a new full clinical study
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Subscribe To Our Newsletter & Stay Updated
